HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.
about
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks.Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
P2860
HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
HER2-positivity rates in breas ...... atures and testing are stable.
@en
type
label
HER2-positivity rates in breas ...... atures and testing are stable.
@en
prefLabel
HER2-positivity rates in breas ...... atures and testing are stable.
@en
P2093
P2860
P356
P1476
HER2-positivity rates in breas ...... atures and testing are stable.
@en
P2093
C Charon-Barra
C Loustalot
F Beltjens
I Desmoulins
P Fumoleau
S Pigeonnat
P2860
P356
10.1111/ECC.12404
P407
P577
2015-10-27T00:00:00Z